Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Chief Product Officer | September 16, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,390 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 2,650 · Balance 177,390 F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 20:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 2,650 | $22.00 | $58,300.00 |
DisclosureSEC source: 0002048500-26-000013 · form4-09172026_040904.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,390 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025. Read SEC document |
| September 02, 2026 Filed Sep 3, 2026 22:15 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,375 | $19.11 | $83,619.81 |
DisclosureSEC source: 0002048500-26-000012 · form4-09032026_060904.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,040 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $19.1131 and the range of prices were between $18.89 and $19.545. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 22:13 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 4,378 | $12.61 | $55,193.88 |
DisclosureSEC source: 0002048500-26-000009 · form4-06032026_100646.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,415 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,064 | $12.36 | $13,152.74 |
DisclosureSEC source: 0002048500-26-000004 · form4-03032026_060306.xml · nonDerivative · entry 2 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,793 F2 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 58,749 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002048500-26-000004 · form4-03032026_060306.xml · derivative · entry 3 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,749 Underlying: Common Stock · 58,749 shares Expires 2036-02-26 F4 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 23:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 109,105 | $0.00 | $0.00 |
DisclosureSEC source: 0002048500-26-000004 · form4-03032026_060306.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,857 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| February 27, 2026 Filed Mar 13, 2026 20:15 UTC Amendment | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 91,520 | $0.00 Strike: $12.63 | $0.00 |
DisclosureSEC source: 0002048500-26-000006 · form4a-03132026_040314.xml · derivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,520 Underlying: Common Stock · 91,520 shares Expires 2036-02-26 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:16 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 2,200 | $30.10 | $66,221.10 |
DisclosureSEC source: 0002048500-26-000003 · form4-01072026_090132.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,752 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025. F2 · price: The weighted average sale price for the transaction reported was $30.1005 and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:05 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 600 | $30.20 | $18,118.14 |
DisclosureSEC source: 0002048500-26-000002 · form4-01052026_110121.xml · nonDerivative · entry 2 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,952 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025. F3 · price: The weighted average sale price for the transaction reported was $30.1969 and the range of prices were between $30.10 and $30.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:05 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 7,200 | $29.56 | $212,832.00 |
DisclosureSEC source: 0002048500-26-000002 · form4-01052026_110121.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,552 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025. F2 · price: The weighted average sale price for the transaction reported was $29.56 and the range of prices were between $29.05 and $30.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:20 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,063 | $29.34 | $31,184.06 |
DisclosureSEC source: 0002048500-25-000004 · form4-12042025_041205.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,752 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,089 | $18.86 | $20,542.02 |
DisclosureSEC source: 0001415889-25-023744 · form4-09042025_060906.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,815 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 101 | $18.69 | $1,887.79 |
DisclosureSEC source: 0001415889-25-015668 · form4-06042025_070612.xml · nonDerivative · entry 3 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,904 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F4 · price: The weighted average sale price for the transaction reported was $18.691 and the range of prices were between $18.69 and $18.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 708 | $18.15 | $12,849.42 |
DisclosureSEC source: 0001415889-25-015668 · form4-06042025_070612.xml · nonDerivative · entry 2 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,005 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $18.1489 and the range of prices were between $17.62 and $18.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 23:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 306 | $17.03 | $5,210.57 |
DisclosureSEC source: 0001415889-25-015668 · form4-06042025_070612.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,713 F1 · kind: The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $17.028 and the range of prices were between $16.62 and $17.56. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $19.91 | $0.00 |
DisclosureSEC source: 0001415889-25-006232 · form4-03032025_050306.xml · derivative · entry 2 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2035-02-26 F2 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from February 27, 2025. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 22:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006232 · form4-03032025_050306.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,019 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 110,278 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 9 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,278 Underlying: Common Stock · 110,278 shares Expires 2025-01-28 F7 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F6 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 236,553 | $0.00 Strike: $5.10 | $0.00 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 8 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,553 Underlying: Common Stock · 236,553 shares Expires 2033-09-13 F5 · derivative.exercise_date: One-fourth of the shares subject to this option shall vest one year after August 1, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof. F6 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | OtherClass B Common Stock Warrant (right to buy) · Derivative | 10,575 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 7 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2033-08-27 F4 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | ConversionClass B Common Stock Warrant (right to buy) · Derivative | 10,575 | $0.00 Strike: $0.02 | $0.00 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 6 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,575 Underlying: Common Stock · 10,575 shares Expires 2033-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this warrant was converted into an equal number of shares of Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | ConversionSeries D Preferred Stock · Derivative | 15,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · derivative · entry 5 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | PurchaseCommon Stock | 33,350 | $17.00 | $566,950.00 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 4 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,019 F3 · kind: The shares were purchased in the Issuer's initial public offering. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 13 | $17.00 | $221.00 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 3 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,669 F2 · kind: On January 31, 2025, the reporting person exercised a warrant to purchase 10,575 shares of Issuer's common stock for $0.02 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in withholding of 13 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 10,562 shares. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | OtherCommon Stock | 10,575 | $0.02 | $211.50 |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 2 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,682 Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | ConversionCommon Stock | 15,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002819 · form4-02032025_080211.xml · nonDerivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the initial public offering, each share of Series D Preferred Stock (the "Preferred Stock") was converted into an equal number of shares of Class B Common Stock and subsequently was converted into an equal number of shares of Common Stock without payment of further consideration. The Preferred Stock had no expiration date. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:32 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantEmployee Stock Option (right to buy) · Derivative | 110,278 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002481 · form4-01312025_090141.xml · derivative · entry 1 Mensinger Mike · CIK 0002048500 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,278 Underlying: Class B Common Stock · 110,278 shares Expires 2035-01-28 F1 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 29, 2025 in equal monthly amounts. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.